reports
- Jonathan Moreland
PCTY PAYLOCITY HOLDING CORP.
LXRX LEXICON PHARMACEUTICALS INC.
FAF FIRST AMERICAN FINANCIAL CORPORATION
MEDP MEDPACE HOLDINGS INC.
PRU PRUDENTIAL PLC
SAH SONIC AUTOMOTIVE INC. CLASS A
MSFT MICROSOFT CORPORATION
SSTI SHOTSPOTTER
KKR KKR & CO. INC.
DKNG DRAFTKINGS INC
VERX VERTEX
DLHC INC.
FLYW DALEIGH HOLDINGS CORP
WRB FLYWIRE CORP
IE W.R. BERKLEY CORPORATION
NPWR IVANHOE ELECTRIC INC
GDV NET POWER INC
THE GABELLI DIVIDEND & INCOME TRUST
- Jonathan Moreland
VRNS VARONIS SYSTEMS INC.
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TWI TITAN INTERNATIONAL INC.
SLP SIMULATIONS PLUS
SCSC SCANSOURCE INC.
PSEC PROSPECT CAPITAL CORPORATION
PAYX PAYCHEX INC.
NG. NOVAGOLD RESOURCES INC.
MOH MOLINA HEALTHCARE INC.
MMS MAXIMUS INC.
LMAT LEMAITRE VASCULAR INC.
KVHI KVH INDUSTRIES INC.
GKOS GLAUKOS CORP
CINF CINCINNATI FINANCIAL CORPORATION
BMI BADGER METER INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
ARCC ARES CAPITAL CORPORATION
ASA ASA
PRU PRUDENTIAL PLC
TSI TCW STRATEGIC INCOME FUND INC.
PLBC PLUMAS BANCORP
GRF EAGLE CAPITAL GROWTH FUND INC
LW LAMB WESTON HOLDINGS INC.
HWKN HAWKINS INC.
WDFC WD-40 COMPANY
PW POWER REIT
ABT ABBOTT LABORATORIES
KKR KKR & CO. INC.
AXR AMREP
SONO SONOS
TENB TENABLE HOLDINGS
AVTR AVANTOR
CMTV INC.
AON COMMUNITY BANCORP INC. VT
BSTZ AON PLC CLASS A
AFRM BLACKROCK SCIENCE AND TECHNOLOGY TRUST II
INTA AFFIRM HOLDINGS
TMC INTAPP INC
CHRW TMC THE METALS CO INC
TBBK C.H. ROBINSON WORLDWIDE
FRST INC.
QDEL THE BANCORP
CHUC INC.
PMN PRIMIS FINANCIAL CORP
HYMC QUIDEL CORP
CING CHARLIES HLDGS INC
SPGI PROMIS NEUROSCIENCES INC.
HYCROFT MINING HOLDING CORPORATION
CINGULATE INC
MCGRAW HILL FINANCIAL INC
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
CINF CINCINNATI FINANCIAL CORPORATION
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
TSI TCW STRATEGIC INCOME FUND INC.
PLBC PLUMAS BANCORP
AXR AMREP
TENB TENABLE HOLDINGS
CMTV COMMUNITY BANCORP INC. VT
DLHC DALEIGH HOLDINGS CORP
CHRW C.H. ROBINSON WORLDWIDE
QDEL INC.
WRB QUIDEL CORP
CHUC W.R. BERKLEY CORPORATION
CHARLIES HLDGS INC
Prospect Capital Corp: 1 director
A director at Prospect Capital Corp bought 942,800 shares at 2.917USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Donna Karan New York Presents The Edit, the Spring 2026 Campaign Featu...
Donna Karan New York Presents The Edit, the Spring 2026 Campaign Featuring Adriana Lima, Joan Smalls and Grace Elizabeth NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Donna Karan New York continues its reemergence with The Edit: a curated fashion campaign shaped by three women whose presence transcends trend, age, and moment. Adriana Lima, Joan Smalls, and Grace Elizabeth bring their distinct points of view to the brand’s design DNA, selecting and styling a personal edit from the wider collection for an intimate dialogue between women and their wardrobes. Highlighting the talents’ pe...
DKNY Reveals Its Spring 2026 Campaign Featuring Hailey Bieber
DKNY Reveals Its Spring 2026 Campaign Featuring Hailey Bieber NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- The icon is back: Hailey Bieber returns as the global face of DKNY, continuing last season’s breakthrough fashion story with a new, high-impact campaign. For Spring 2026, the disruptive art scene of downtown New York in the ’60s sets the stage for a fresh spin on the recreation of an icon. Expanding on fame as an art form, the campaign places Hailey at the center of a black-and-white photo series of herself while wearing looks from the latest collection. The campaign concept tak...
Prospect Capital Announces Financial Results for December 2025
Prospect Capital Announces Financial Results for December 2025 NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended December 31, 2025. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted average basis for period numbers)Quarter EndedQuarter EndedQuarter Ended December 31, 2025September 30, 2025December 31, 2024 Net Investment Income (“NII”)$90,888$79,350$86,431NII per Common Share$0.19$0.17$0.20Interest as % of Total Investment Income8...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan...
Prospect Capital Schedules Second Fiscal Quarter Earnings Release and ...
Prospect Capital Schedules Second Fiscal Quarter Earnings Release and Conference Call NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (the “Company” or “Prospect”) today announced it expects to file with the Securities and Exchange Commission its report on Form 10-Q containing results for the fiscal quarter ended December 31, 2025 and to issue its earnings press release on Monday, February 9, 2026, after the close of the markets. The Company will host a conference call on Tuesday, February 10, 2026 at 9:00 a.m. Eastern Time. The conference call dia...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of February 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and w...
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Comme...
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. “We are pleased to welcome Matt to the executive team as w...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan...
Prospect Capital Announces Annual Meeting Update
Prospect Capital Announces Annual Meeting Update NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that it held its adjourned annual meeting of stockholders (the “Annual Meeting”) on January 8, 2026. The proposals that were considered at the Annual Meeting are described in detail in the Company’s definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on September 18, 2025 (the “Proxy”). As of September 17, 2025, there were 465,087,009 shares of the Company's c...
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Health...
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. The management team will also participate in one-on-one investo...
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milesto...
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximat...
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biolog...
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN. BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments fo...
- Jonathan Moreland
WHF WHITEHORSE FINANCE INC.
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
LTC LTC PROPERTIES INC.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
DAKT DAKTRONICS INC.
CUBE CUBESMART
AZO AUTOZONE INC.
ASA ASA
ADC AGREE REALTY CORPORATION
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ULBI NIKE INC. CLASS B
FGBI ULTRALIFE
KOD FIRST GUARANTY BANCSHARES
EML KODIAK SCIENCES
MIDD THE EASTERN COMPANY
PHR THE MIDDLEBY CORPORATION
DHC PHREESIA
ALT DIVERSIFIED HEALTHCARE TRUST
COO ALTIMMUNE INC
AZYO THE COOPER COMPANIES INC.
DLHC AZIYO BIOLOGICS
IMNM DALEIGH HOLDINGS CORP
WRB IMMUNOME
MAIA W.R. BERKLEY CORPORATION
KVUE MAIA BIOTECHNOLOGY INC
GTE KENVUE INC
NBBK GRAN TIERRA ENERGY INC.
SUNS NB BANCORP INC.
ASST SUNRISE REALTY TRUST
MPTI ASSET ENTITIES INC.
M-TRON INDUSTRIES
INC.
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and we...
- Jonathan Moreland
AAON AAON INC.
WHF WHITEHORSE FINANCE INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
CUBE CUBESMART
CLFD CLEARFIELD INC.
AZO AUTOZONE INC.
ASA ASA
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
WMG WARNER MUSIC GROUP CORP.
NKE NIKE INC. CLASS B
DIS THE WALT DISNEY COMPANY
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
KOD KODIAK SCIENCES
EML THE EASTERN COMPANY
MIDD THE MIDDLEBY CORPORATION
PHR PHREESIA
DHC DIVERSIFIED HEALTHCARE TRUST
ALT ALTIMMUNE INC
COO THE COOPER COMPANIES INC.
RZLT REZOLUTE
AZYO INC.
DLHC AZIYO BIOLOGICS
AMR DALEIGH HOLDINGS CORP
BMEA ALPHA METALLURGICAL RESOURCES INC
WRB BIOMEA FUSION
NUVL INC.
MAIA W.R. BERKLEY CORPORATION
KVUE NUVALENT INC
GTE MAIA BIOTECHNOLOGY INC
NBBK KENVUE INC
SI GRAN TIERRA ENERGY INC.
ASST NB BANCORP INC.
MPTI SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
M-TRON INDUSTRIES
INC.
Live Ventures Inc: 1 director
A director at Live Ventures Inc sold 3,343 shares at 15.703USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.